{"id":"placebo-of-bacillus-calmette-guerin","safety":{"commonSideEffects":[{"rate":"null","effect":"Local reaction at injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BCG vaccine works by introducing a weakened form of the bacteria that causes tuberculosis, which triggers an immune response that helps the body fight off the infection. This immune response is thought to provide long-term protection against severe forms of tuberculosis, such as TB meningitis and miliary TB. The exact mechanisms of how BCG vaccine provides protection against tuberculosis are not fully understood.","oneSentence":"The Bacillus Calmette-Guérin (BCG) vaccine is a live attenuated vaccine that stimulates a cell-mediated immune response against Mycobacterium tuberculosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:36.015Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe forms of tuberculosis, such as TB meningitis and miliary TB"}]},"trialDetails":[{"nctId":"NCT05547464","phase":"PHASE1, PHASE2","title":"Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2023-07-31","conditions":"Tuberculosis","enrollment":497},{"nctId":"NCT06050356","phase":"PHASE1","title":"First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b","status":"ACTIVE_NOT_RECRUITING","sponsor":"Statens Serum Institut","startDate":"2024-03-14","conditions":"Healthy","enrollment":140},{"nctId":"NCT05591339","phase":"PHASE4","title":"Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bandim Health Project","startDate":"2023-12-01","conditions":"Diabetes Mellitus, BCG Vaccination Reaction","enrollment":200},{"nctId":"NCT04453293","phase":"PHASE3","title":"Immunization With BCG Vaccine to Prevent Tuberculosis Infection","status":"TERMINATED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2021-12-01","conditions":"Tuberculosis Infection","enrollment":16},{"nctId":"NCT05537038","phase":"PHASE1","title":"Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-04-18","conditions":"Tuberculosis","enrollment":120},{"nctId":"NCT05327647","phase":"PHASE2","title":"A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2022-06-23","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":160},{"nctId":"NCT05180591","phase":"PHASE2","title":"Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-03-22","conditions":"Diabetes Mellitus, Type 1, Diabetes type1, Autoimmune Diabetes","enrollment":150},{"nctId":"NCT05866536","phase":"PHASE2","title":"Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-05-04","conditions":"Diabetes Mellitus, Type 1 Diabetes, Diabetes type1","enrollment":100},{"nctId":"NCT06148025","phase":"PHASE4","title":"Antibiotics and Vaccine Immune Responses Study","status":"RECRUITING","sponsor":"South Australian Health and Medical Research Institute","startDate":"2023-11-23","conditions":"Vaccine Response Impaired","enrollment":348},{"nctId":"NCT04149574","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2020-01-15","conditions":"Urinary Bladder Neoplasms","enrollment":13},{"nctId":"NCT05539989","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa","status":"WITHDRAWN","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2025-12-31","conditions":"Tuberculosis, HIV Infections","enrollment":""},{"nctId":"NCT05507671","phase":"PHASE3","title":"The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2021-05-27","conditions":"COVID-19","enrollment":556},{"nctId":"NCT07094711","phase":"PHASE2","title":"Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2025-09-30","conditions":"Mycobacterium Avium-intracellulare Infection, Mycobacterium Infections, Nontuberculous","enrollment":48},{"nctId":"NCT04152161","phase":"PHASE2","title":"Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection","status":"TERMINATED","sponsor":"Gates Medical Research Institute","startDate":"2019-10-16","conditions":"Tuberculosis","enrollment":1836},{"nctId":"NCT06714513","phase":"PHASE1","title":"ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74","status":"RECRUITING","sponsor":"Quratis Inc.","startDate":"2025-05-09","conditions":"Tuberculosis, Pulmonary","enrollment":144},{"nctId":"NCT03152903","phase":"PHASE2, PHASE3","title":"Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2017-12-15","conditions":"Prevention of TB Recurrence","enrollment":2000},{"nctId":"NCT05387655","phase":"","title":"Long Term Effects of BCG Vaccination on Infectious and Immune Mediated Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2022-05-20","conditions":"BCG Vaccination Reaction, Infections, Inflammation","enrollment":4292},{"nctId":"NCT06873282","phase":"PHASE2","title":"Phase 2 Study of the ТВ/Flu-05Е Tuberculosis Vaccine","status":"COMPLETED","sponsor":"Research Institute of Influenza, Russia","startDate":"2023-12-13","conditions":"Tuberculosis","enrollment":160},{"nctId":"NCT04806178","phase":"PHASE3","title":"Immunological Response of Bladder Cancer Patients Under BCG","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2021-09-03","conditions":"Bladder Cancer, Bacillus Calmette-Guerin","enrollment":30},{"nctId":"NCT03888924","phase":"PHASE2","title":"Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)","status":"RECRUITING","sponsor":"S. Andrea Hospital","startDate":"2019-06-17","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT06628544","phase":"EARLY_PHASE1","title":"Trained Immunity in Fungal Infection and Its Mechanism","status":"COMPLETED","sponsor":"Zhongnan Hospital","startDate":"2020-09-01","conditions":"BCG Vaccination","enrollment":79},{"nctId":"NCT04348370","phase":"PHASE4","title":"BCG Vaccine for Health Care Workers as Defense Against COVID 19","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2020-04-20","conditions":"Coronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified Elsewhere","enrollment":659},{"nctId":"NCT05945498","phase":"PHASE1","title":"Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years","status":"COMPLETED","sponsor":"Tatyana Zubkova","startDate":"2023-05-10","conditions":"Tuberculosis Infection","enrollment":51},{"nctId":"NCT04899765","phase":"PHASE4","title":"Measles and BCG Vaccines for Mother and Child","status":"RECRUITING","sponsor":"Bandim Health Project","startDate":"2021-05-20","conditions":"Vaccine Preventable Disease, Measles, Mother-Infant Interaction","enrollment":2400},{"nctId":"NCT03912207","phase":"PHASE1","title":"Investigating Immune Responses to Aerosol BCG Challenge in Healthy UK Adults","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2019-04-19","conditions":"Tuberculosis","enrollment":94},{"nctId":"NCT04369794","phase":"PHASE4","title":"COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2020-10-01","conditions":"COVID-19, Therapeutic Vaccine, BCG","enrollment":400},{"nctId":"NCT05284812","phase":"PHASE2","title":"A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)","status":"SUSPENDED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2022-02-10","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT02709278","phase":"PHASE1","title":"Aerosol BCG Challenge Trial in Healthy UK Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2016-03-07","conditions":"Tuberculosis","enrollment":46},{"nctId":"NCT03191578","phase":"PHASE1","title":"Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI®","status":"COMPLETED","sponsor":"Archivel Farma S.L.","startDate":"2017-06-16","conditions":"High-Risk Non-Muscle-Invasive Bladder Cancer","enrollment":44},{"nctId":"NCT04659941","phase":"PHASE2","title":"Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers","status":"UNKNOWN","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2020-10-01","conditions":"COVID 19 Vaccine","enrollment":752},{"nctId":"NCT04563273","phase":"PHASE1","title":"Clinical Study of BCG Vaccine for Intradermal Injection","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2020-10-21","conditions":"Tuberculosis","enrollment":160},{"nctId":"NCT05004038","phase":"PHASE2","title":"BCG Vaccination Effect on Latent Reservoir Size in Treated HIV-1 Infection:","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2022-01-04","conditions":"HIV-1-infection","enrollment":60},{"nctId":"NCT05468606","phase":"EARLY_PHASE1","title":"Coadministration of GA2 Sporozoites With Adjuvants","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2023-02-03","conditions":"Malaria,Falciparum","enrollment":45},{"nctId":"NCT04641858","phase":"PHASE4","title":"BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic","status":"COMPLETED","sponsor":"University of Southern Denmark","startDate":"2020-12-03","conditions":"Covid19, Morbidity, Absenteeism","enrollment":668},{"nctId":"NCT04537663","phase":"PHASE4","title":"Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-07","conditions":"Respiratory Tract Infections, Covid19","enrollment":6112},{"nctId":"NCT05490082","phase":"PHASE3","title":"Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2022-03-01","conditions":"Voiding Disorders","enrollment":100},{"nctId":"NCT04938323","phase":"PHASE2, PHASE3","title":"Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly","status":"WITHDRAWN","sponsor":"Harvard Medical School (HMS and HSDM)","startDate":"2022-05","conditions":"Acute Respiratory Infection","enrollment":""},{"nctId":"NCT04328441","phase":"PHASE3","title":"Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-03-25","conditions":"COVID-19","enrollment":1511},{"nctId":"NCT04439045","phase":"PHASE3","title":"Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2020-06-24","conditions":"SARS-CoV-2 Infection","enrollment":122},{"nctId":"NCT03549650","phase":"PHASE2","title":"Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms","status":"TERMINATED","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2019-05-03","conditions":"Lower Urinary Tract Symptoms, Bladder Carcinoma, BCG","enrollment":3},{"nctId":"NCT04379336","phase":"PHASE3","title":"BCG Vaccination for Healthcare Workers in COVID-19 Pandemic","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2020-05-04","conditions":"COVID-19, Sars-CoV2","enrollment":1000},{"nctId":"NCT04435379","phase":"PHASE3","title":"Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic","status":"COMPLETED","sponsor":"Serum Life Science Europe GmbH","startDate":"2020-06-18","conditions":"Infection, Respiratory Tract","enrollment":2038},{"nctId":"NCT04373291","phase":"PHASE3","title":"Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2020-05-18","conditions":"COVID-19, Non-specific Effects of Vaccines, Morbidity","enrollment":1293},{"nctId":"NCT04534803","phase":"PHASE3","title":"BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST)","status":"WITHDRAWN","sponsor":"Harvard Medical School (HMS and HSDM)","startDate":"2021-09","conditions":"Covid19","enrollment":""},{"nctId":"NCT04414267","phase":"PHASE4","title":"Bacillus Calmette-guérin Vaccination to Prevent COVID-19","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2020-05-26","conditions":"COVID-19, Virus Diseases, Corona Virus Infection","enrollment":301},{"nctId":"NCT02712424","phase":"PHASE2","title":"DAR-901 TB Booster Vaccine to Prevent TB in Adolescents","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2016-03","conditions":"Tuberculosis","enrollment":625},{"nctId":"NCT02953327","phase":"PHASE4","title":"Testing if BCG (Bacille Calmette-Guérin) Vaccination Can Induce Innate Immune Training in Adult People Above 50 Years of Age in Guinea-Bissau","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2017-02-01","conditions":"Innate Immunity, Bacille Calmette-Guérin","enrollment":40},{"nctId":"NCT04632537","phase":"PHASE3","title":"BCG Vaccination to Prevent COVID-19","status":"WITHDRAWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2020-12-07","conditions":"COVID-19","enrollment":""},{"nctId":"NCT03296423","phase":"PHASE4","title":"Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2017-09-21","conditions":"Infection, Hospitalization, Mortality","enrollment":200},{"nctId":"NCT04648800","phase":"PHASE3","title":"Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland","status":"UNKNOWN","sponsor":"Hanna Czajka","startDate":"2020-07-07","conditions":"Covid19, BCG Vaccination Reaction, SARS-CoV Infection","enrollment":1000},{"nctId":"NCT04362124","phase":"PHASE3","title":"Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of COVID-19 Infection.","status":"WITHDRAWN","sponsor":"Universidad de Antioquia","startDate":"2020-08","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04461379","phase":"PHASE3","title":"Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers","status":"UNKNOWN","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2020-07-21","conditions":"BCG, COVID-19, SARS-CoV2","enrollment":908},{"nctId":"NCT02795260","phase":"PHASE3","title":"Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2016-05","conditions":"Tuberculosis","enrollment":1802},{"nctId":"NCT04387409","phase":"PHASE3","title":"Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic","status":"UNKNOWN","sponsor":"Serum Life Science Europe GmbH","startDate":"2020-05-25","conditions":"Infection, Respiratory Tract","enrollment":59},{"nctId":"NCT04121494","phase":"EARLY_PHASE1","title":"ChAdOx1 85A Aerosol Versus Intramuscular Vaccination in Healthy Adults (TB039)","status":"COMPLETED","sponsor":"François Spertini","startDate":"2019-01-22","conditions":"Mycobacterium Tuberculosis, Protection Against, Tuberculosis","enrollment":39},{"nctId":"NCT04384549","phase":"PHASE3","title":"Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-05-20","conditions":"Infection, Viral, Agent as Cause of Disease Classified Elsewhere","enrollment":1120},{"nctId":"NCT04417335","phase":"PHASE4","title":"Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2020-04-16","conditions":"COVID-19","enrollment":2014},{"nctId":"NCT04350931","phase":"PHASE3","title":"Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2020-04-20","conditions":"Coronavirus Disease (COVID-19)","enrollment":900},{"nctId":"NCT02010203","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT","status":"TERMINATED","sponsor":"Heat Biologics","startDate":"2013-12","conditions":"Bladder Cancer","enrollment":104},{"nctId":"NCT01865487","phase":"PHASE1, PHASE2","title":"A Phase I/IIa AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456)","status":"COMPLETED","sponsor":"Aeras","startDate":"2013-08","conditions":"Latent Tuberculosis Bacteriology and Histology Unknown, Latent Tuberculosis","enrollment":98},{"nctId":"NCT02378207","phase":"PHASE1","title":"Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents","status":"COMPLETED","sponsor":"Aeras","startDate":"2015-05","conditions":"Tuberculosis","enrollment":84},{"nctId":"NCT00396370","phase":"PHASE1","title":"BCG Vaccination Delivered Intradermally, Orally and by Combined Routes","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-12-02","conditions":"Tuberculosis","enrollment":69},{"nctId":"NCT02075203","phase":"PHASE2","title":"Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents","status":"COMPLETED","sponsor":"Aeras","startDate":"2014-02","conditions":"Tuberculosis","enrollment":989},{"nctId":"NCT03806699","phase":"PHASE1","title":"Phase 1 Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent","status":"UNKNOWN","sponsor":"Quratis Inc.","startDate":"2019-04-02","conditions":"Tuberculosis","enrollment":36},{"nctId":"NCT03806686","phase":"PHASE2","title":"Phase 2a Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers","status":"UNKNOWN","sponsor":"Quratis Inc.","startDate":"2018-05-31","conditions":"Tuberculosis","enrollment":107},{"nctId":"NCT01861730","phase":"PHASE1, PHASE2","title":"Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants","status":"COMPLETED","sponsor":"Aeras","startDate":"2013-07-01","conditions":"Tuberculosis","enrollment":243},{"nctId":"NCT00529633","phase":"PHASE3","title":"The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients","status":"TERMINATED","sponsor":"George A. Kaysen, M.D.","startDate":"2007-09","conditions":"Hypoalbuminemia","enrollment":16},{"nctId":"NCT01927159","phase":"PHASE1","title":"Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Access to Advanced Health Institute (AAHI)","startDate":"2013-09","conditions":"Pulmonary Tuberculosis","enrollment":66},{"nctId":"NCT01694108","phase":"PHASE4","title":"Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children.","status":"COMPLETED","sponsor":"Lone Graff Stensballe","startDate":"2012-09","conditions":"Prospective, Single-blind, Clinical","enrollment":4262},{"nctId":"NCT01198366","phase":"PHASE1, PHASE2","title":"Study of AERAS-402 in Healthy Infants","status":"COMPLETED","sponsor":"Aeras","startDate":"2010-09","conditions":"Tuberculosis","enrollment":487},{"nctId":"NCT02389322","phase":"PHASE2","title":"Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2015-03","conditions":"Tuberculosis","enrollment":1044},{"nctId":"NCT02420444","phase":"PHASE1","title":"A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-Negative, TB-Negative, BCG-Naive Adults","status":"COMPLETED","sponsor":"Aeras","startDate":"2011-01","conditions":"Tuberculosis","enrollment":70},{"nctId":"NCT01017536","phase":"PHASE2","title":"Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults","status":"COMPLETED","sponsor":"Aeras","startDate":"2009-12","conditions":"Tuberculosis, HIV Infections","enrollment":26},{"nctId":"NCT02063555","phase":"PHASE1","title":"Phase I Trial of DAR-901","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2014-02","conditions":"Tuberculosis","enrollment":59},{"nctId":"NCT00953927","phase":"PHASE2","title":"A Study of MVA85A in Healthy Infants","status":"COMPLETED","sponsor":"Aeras","startDate":"2009-07","conditions":"Tuberculosis","enrollment":2797},{"nctId":"NCT02430506","phase":"PHASE1","title":"A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB","status":"COMPLETED","sponsor":"Aeras","startDate":"2008-09","conditions":"Tuberculosis","enrollment":20},{"nctId":"NCT02109874","phase":"PHASE1","title":"A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404)","status":"COMPLETED","sponsor":"Aeras","startDate":"2008-12","conditions":"Tuberculosis","enrollment":40},{"nctId":"NCT00052195","phase":"PHASE2, PHASE3","title":"Investigational Vaccine for the Prevention of Disseminated Tuberculosis in HIV Infected People","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2001-09","conditions":"Tuberculosis, HIV Infections","enrollment":1975},{"nctId":"NCT00477906","phase":"PHASE3","title":"M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma","status":"UNKNOWN","sponsor":"AVAX Technologies","startDate":"2016-07","conditions":"Melanoma","enrollment":387},{"nctId":"NCT02114255","phase":"PHASE2, PHASE3","title":"Effects of BCG on Influenza Induced Immune Response","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2014-05","conditions":"Influenza Virus Infection, Trained Immunity","enrollment":40},{"nctId":"NCT02375256","phase":"PHASE1","title":"A Leukapheresis Study for Immune Responses in Healthy US Adults Who Receive BCG Vaccination Followed by Boosting With AERAS-402","status":"COMPLETED","sponsor":"Aeras","startDate":"2009-10","conditions":"Tuberculosis","enrollment":11},{"nctId":"NCT01583972","phase":"NA","title":"Efficacy of Newborn Vitamin A Supplementation in Improving Immune Function","status":"COMPLETED","sponsor":"USDA, Western Human Nutrition Research Center","startDate":"2012-01","conditions":"Vitamin A Deficiency","enrollment":300},{"nctId":"NCT01378312","phase":"PHASE1","title":"A Study to Evaluate Safety and Immunogenicity of AERAS-402","status":"COMPLETED","sponsor":"Aeras","startDate":"2011-02","conditions":"Tuberculosis","enrollment":12},{"nctId":"NCT02074956","phase":"PHASE1","title":"A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults","status":"COMPLETED","sponsor":"Aeras","startDate":"2008-05","conditions":"Tuberculosis","enrollment":60},{"nctId":"NCT02066428","phase":"PHASE1","title":"A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection","status":"COMPLETED","sponsor":"Aeras","startDate":"2007-11","conditions":"Tuberculosis","enrollment":64},{"nctId":"NCT01779180","phase":"","title":"Vitamin A Supplementation at Birth and Atopy in Childhood","status":"UNKNOWN","sponsor":"Bandim Health Project","startDate":"2013-01","conditions":"Atopy, Asthma, Eczema","enrollment":2000},{"nctId":"NCT01497769","phase":"PHASE1","title":"Safety of Tuberculosis Vaccine, MVA85A, Administered by the Aerosol Route and the Intradermal Route","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2011-09","conditions":"Tuberculosis","enrollment":24},{"nctId":"NCT01288950","phase":"NA","title":"Vitamin D Supplementation Enhances Immune Response to Bacille-Calmette-Guerin (BCG) Vaccination in Infants","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2011-02","conditions":"Tuberculosis","enrollment":49},{"nctId":"NCT00514072","phase":"PHASE2","title":"Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer","status":"UNKNOWN","sponsor":"Kael-GemVax Co., Ltd.","startDate":"2007-03","conditions":"Prostate Cancer","enrollment":54},{"nctId":"NCT01542567","phase":"PHASE3","title":"Efficacy of Diclofenac BCG Irrigations","status":"UNKNOWN","sponsor":"Carmel Medical Center","startDate":"2012-05","conditions":"Bladder Cancer","enrollment":100},{"nctId":"NCT00202410","phase":"PHASE2, PHASE3","title":"Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis","status":"COMPLETED","sponsor":"S. Andrea Hospital","startDate":"2001-11","conditions":"Multiple Sclerosis","enrollment":80},{"nctId":"NCT00429715","phase":"PHASE2, PHASE3","title":"Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2007-01","conditions":"Healthy","enrollment":150},{"nctId":"NCT00429780","phase":"PHASE2, PHASE3","title":"Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0)","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2007-01","conditions":"Healthy","enrollment":100},{"nctId":"NCT00052130","phase":"PHASE3","title":"Vaccine Therapy for Patients With Stage III Melanoma","status":"UNKNOWN","sponsor":"CancerVax Corporation","startDate":"","conditions":"Malignant Melanoma","enrollment":1118},{"nctId":"NCT00052156","phase":"PHASE3","title":"Vaccine Therapy for Patients With Stage IV Melanoma","status":"UNKNOWN","sponsor":"CancerVax Corporation","startDate":"","conditions":"Malignant Melanoma","enrollment":670}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["placebo of BCG"],"phase":"phase_3","status":"active","brandName":"placebo of Bacillus Calmette - Guerin","genericName":"placebo of Bacillus Calmette - Guerin","companyName":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","companyId":"anhui-zhifei-longcom-biologic-pharmacy-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"The Bacillus Calmette-Guérin (BCG) vaccine is a live attenuated vaccine that stimulates a cell-mediated immune response against Mycobacterium tuberculosis. Used for Severe forms of tuberculosis, such as TB meningitis and miliary TB.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}